This multicenter study was designed to evaluate whether allo-PBPCT provides some advantages, if any, over BMT in terms of engraftment kinetics, acute and chronic GVHD incidence, TRM, relapse incidence and survival in acute lymphoblastic leukemia patients (ALL). From January 1995 to December 1999, 67 ALL patients (34 in the PBPCT group and 33 in the BMT group) were included in this study. Median age for both groups was 8 years (range, 1-18). There were 24 patients in first or second CR in the PBPCT group and 28 such patients in the BMT group. Preparatory regimens were TBI-based in 26/34 in the PBPC group and 25/33 in the BMT group. GVHD prophylaxis was CsA alone in 38 patients (18 PBPCT vs 20 BMT) and CsA plus short Mtx in 29 (16 PBPCT vs 13 BMT). Engraftment was achieved in all cases. Median days to neutrophil recovery was 10 (range, 7-18) after PBPCT vs 14 (range, 9-21) after BMT (P Ͻ 0.0001). Platelet engraftment (Ͼ50 ؋ 10 9 /l) was also faster for PBPCT patients (median 13 days, range, 9-40 vs 23 days, range, 15-165) (P Ͻ 0.0001). Acute GVHD grade II-IV incidence was similar in both groups (46.4 ؎ 8.8% vs 42.7 ؎ 8.6%) (P ‫؍‬ 0.45). Probability of chronic GVHD was 50.6 ؎ 12.2% after PBPCT vs 27.8 ؎ 9.2% after BMT (P ‫؍‬ 0.1). Probability of relapse was similar (28.7 ؎ 9.2% for PBPCT vs 27.1 ؎ 8.2% for BMT) (P ‫؍‬ 0.89). There were eight patients who died from transplantrelated complications after PBPCT vs 5 after BMT (P, NS). With a median follow-up of 25 months the eventfree survival probability was 53 ؎ 8.9% for PBPCT vs 54.9 ؎ 9.7% for BMT (P ‫؍‬ 0.54). Using PBPC for allogeneic transplantation in childhood ALL results in faster hematopoietic recovery compared to BM, with a similar incidence of aGVHD, TRM, relapse and disease- 
free survival. However, the issue of cGVHD remains unresolved. Bone Marrow Transplantation (2002) 30, 9-13. doi: 10.1038/sj.bmt.1703589 Keywords: allogeneic transplantation; peripheral blood progenitor cell; bone marrow; childhood acute lymphoblastic leukemia Allogeneic bone marrow transplantation is an accepted therapeutic option for pediatric patients with high risk acute lymphoblastic leukemia (ALL). [1] [2] [3] [4] [5] [6] Since the mid-1990s we have witnessed the increasing use of cytokine-mobilized peripheral blood as an alternative to bone marrow for allogeneic transplantation. Previous reports of allogeneic PBPC transplantation (allo-PBPCT) clearly show that this therapeutic procedure provides faster hematopoietic engraftment than allogeneic bone marrow transplantation (BMT) and a similar incidence of acute graft-versus-host disease (GVHD), although a PBPC graft contains 1 log more lymphocytes than does a bone marrow harvest. In these studies, allo-PBPCT was used mainly in adult patients with advanced hematological malignancies. [7] [8] [9] [10] [11] [12] However, there is very limited reported experience using allo-PBPCT in pediatric patients. Data from these reports suggest that allo-PBPCT appears safe in pediatric patients and donors, and it seems not to be associated with an increase in acute GVHD. [13] [14] [15] [16] [17] Taking into account these considerations, we conducted a case-control study in pediatric patients with ALL comparing blood and bone marrow as sources of stem cells for allografting. Endpoints of this study were engraftment kinetics, acute and chronic GVHD incidence, transplant-related mortality (TRM), risk of relapse and event-free survival (EFS).
Patients, donors and methods
From January 1995 to December 2000, 67 ALL patients (34 PBPCT group and 33 BMT) were included in this study. Controls (BMT patients) were selected from differ- ent participating centers by closely matching for recipient age and gender, CMV status, disease status at transplantation, preparative regimen and GVHD prophylaxis (Table  1) . Persons making the patient selection (BMT patients) did not know their clinical outcome. Donor characteristics are shown in Table 2 . All donors were HLA-identical relatives (65 siblings, one father, one uncle). Informed consent was given by patients and donors, parents or guardians as appropriate.
Bone marrow harvest, PBPC mobilization and collection
Bone marrow cells were collected under general anesthesia by standard procedures. Red cells were depleted from the graft in cases of donor-recipient ABO incompatibility. PBPC donors were mobilized by granulocyte colony-stimulating factor (G-CSF) given subcutaneously at a dose of 10 g/kg/day for 4 or 5 days. Apheresis were performed on day 5 of mobilization using a Fenwall CS-3000 PLUS (Baxter, Round Lake, IL, USA) or Cobe Spectra (COBE BCT, Lakewood, CO, USA) cell separator. CD34 ϩ cell counts in the apheresis products were determined by flow cytometry. Data regarding PBPC mobilization and collections on healthy donors are systematically sent to the Spanish National Donor Registry. The tolerance and safety profile of PBPC mobilization and collection in pediatric donors has been previously reported.
18-20
Conditioning, transplant procedure and supportive care
Marrow and PBPC recipients were conditioned according to the protocols in use at each institution. Only patients conditioned with busulphan (4 mg/kg/day for 4 days) plus cyclophosphamide (60 mg/kg/day for 2 days) or cyclophosphamide (60 mg/kg/day for 2 days) plus total body irradiation (TBI) 12-13.5 Gy were elegible for analysis. Marrow cells and PBPC were infused on day 0 with no manipulation. Cyclosporine alone or methotrexate and cyclosporine were given as GVHD prophylaxis. Acute and chronic GVHD were diagnosed according to standard criteria. 21, 22 G-CSF post-infusion was given only in the event of delayed or impaired neutrophil engraftment.
Definition of endpoints and statistical analysis
The study was focused on hematopoietic recovery, acute and chronic GVHD incidence, leukemia relapse, TRM and EFS analysis with relation to source of stem cells. For engraftment kinetics analysis, the achievement of neutrophils Ͼ0.5 ϫ 10 9 /l and of platelets Ͼ20 and Ͼ50 ϫ 10 9 /l for 3 consecutive days without transfusion support were considered events. Patients without hematopoietic recovery were censored at time of death or last follow-up. Acute GVHD was evaluated in patients with evidence of engraftment. Chronic GVHD was evaluated in patients surviving 90 days or longer following transplantation, with evidence of engraftment. TRM was defined as any cause of death other than relapse or progressive disease. Relapse was defined as leukemia recurrence after achieving remission. Statistical comparisons between both groups regarding patients and transplant characteristics were performed using the Pearson's chi-squared and Wilcoxon test, as appropriate. The Kaplan and Meier method 23 was used to estimate probability of engraftment and cumulative incidences of acute and chronic GVHD, relapse, TRM and survival. Curves comparison was performed using the logrank test.
Results

Engraftment
All recipients attained neutrophil engraftment. Times to neutrophil and platelet recovery are shown in Table 3 . Probabilities of neutrophil engraftment for both groups are shown in Figure 1 . Engraftment kinetics for neutrophils among PBPCT patients were not affected by using methotrexate as GVHD prophylaxis (CsA ϩ Mtx vs CsA hazard ratio 1.228, 95% CI of ratio 0.667-2.66, P ϭ 0.41). No correlation was observed between number of CD34 ϩ cells as a continuous variable in PBPC grafts and time to neutro-11 Table 3 Engraftment kinetics phil and platelet recovery (r ϭ 0.33, P ϭ 0.06 and r ϭ 0.02, P ϭ 0.9 respectively). However, platelet engraftment was significantly faster in patients receiving у5 ϫ 10 6
CD34
ϩ cells/kg compared to those receiving a lower doses (Figure 2 ). 
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Graft-versus-host disease
Rates of grades II-IV acute GVHD were similar in the PBPC and BM groups (16 and 14 patients, respectively, RR ϭ 1.1; 95% CI 0.65-1.89. P ϭ 0.8). The cumulative incidences of grades II-IV GVHD at 100 days were 46.4 Ϯ 8.8% for patients grafted with PBPC compared to 42.7 Ϯ 8.6% for patients in the BM group. Among PBPC recipients, four out of 15 patients who received CsA ϩ Mtx as GVHD prophylaxis developed acute GVHD compared to 12 out of 19 patients receiving CsA alone (RR 0.422, 95% CI 0.17-1.04) (P ϭ 0.04). Six patients in the BM group and eight in the PBPC group had developed chronic GVHD by 1 year after transplantation. Two more PBPC recipients developed chronic GVHD after 1 year post-transplantation. However, there was no significant difference in the cumulative incidence of chronic GVHD at 2 years ( Figure 3 
Transplant-related mortality, relapse and survival
No statistically significant differences in 1 year TRM were observed (25.2% Ϯ 7.7 for PBPCT group vs 24.1 Ϯ 10.2 for BMT; log-rank P ϭ 0.29). The cumulative incidences of relapse at 2 years were 28.7 Ϯ 9.2% for PBPC recipients and 27.1 Ϯ 8.2% for BM patients (PBPC vs BM hazard ratio ϭ 0.93; 95% CI 0.33-2.59; P ϭ 0.89). The EFS at 2 years was 53 Ϯ 8.9% for PBPC patients compared to 54.9 Ϯ 9.7% for BM patients (HR 1.25, 95% CI 0.59-2.65)
Discussion
High risk ALL is the main indication for hematopoietic transplantation in the pediatric age group. Bone marrow has usually been used as the source of stem cells. However, over the last few years mobilized peripheral blood has been used as an alternative source of stem cells for allogeneic transplantation. In adult patients, several retrospective and prospective randomized studies comparing allogeneic blood and bone marrow transplantation have indicated that allo-PBPCT is better than BMT in terms of engraftment kinetics and immune recovery with a similar incidence of acute GVHD, [7] [8] [9] [10] [11] [12] 24 although, issues regarding chronic GVHD incidence are still unresolved. In addition, two recent randomized studies have suggested a potential benefit for allo-PBPCT with respect to relapse and survival without an increased incidence of cGVHD. 25, 26 No similar comparative studies involving pediatric patients have been reported. Our study is a matched-pair study instead of a randomized, prospective study partly because the limited number of suitable sibling donors would never have resulted in sufficient subjects for randomization, and more importantly for ethical reasons since cytokine mobilization of pediatric donors for PBPC collection would probably be considered unethical by some investigators.
This study clearly shows that use of PBPC results in faster hematological recovery. This finding is in agreement with the results of other studies of allo-PBPCT in either adults or children. [7] [8] [9] [10] [11] [12] [24] [25] [26] [27] A possible explanation for this may be the larger numbers of committed progenitors in cytokine-mobilized peripheral blood. As with another matched-pair analysis recently published, 27 we found no relationship between the CD34 ϩ cell dose and neutrophil engraftment. However, platelet engraftment was significantly faster in patients receiving у5 ϫ 10 6 CD34 ϩ cells/kg compared to those receiving a lower dose suggesting that a high number of CD34 ϩ cells should be infused for optimal and rapid hematopoietic recovery.
We observed a similar incidence and severity of aGVHD in both patient groups. This is in accordance with results published from five prospective randomized studies 25, 26, [28] [29] [30] involving adult patients despite a larger number of CD3 ϩ cells being infused to PBPCT patients. Several reasons, apart from GVHD prophylaxis regimen used have been proposed to explain this theoretically paradoxical finding, and in the PBPCT group there was, in fact, a lower incidence of aGVHD among patients who had received cyclosporine plus methotrexate instead of cyclosporine alone. One explanation could be the existence of a biologic plateau effect in spite of the fact that an increased number of CD3 ϩ cells is being infused. 11 Another could be related to the functionally different T lymphocyte populations infused. 31 As experimental and clinical studies have demonstrated, G-CSF mobilization induces T cells to produce type 2 cytokines, which results in a reduced severity of GVHD. 32, 33 Based on this, some investigators 26 have postulated that mobilization with higher doses of G-CSF would result in similar rates of cGVHD compared to those seen after BMT. While the reported incidence of aGVHD with PBPCT is similar compared to BMT, [15] [16] [17] 34, 35 several authors have found an increased incidence of cGVHD. Levine et al 36 found a probability of cGVHD of 75% at 1 year after PBPCT in pediatric patients. However, other authors 37 have recently reported a similar incidence and severity of cGVHD in a group of childhood ALL patients receiving PBPCT compared to a historical group receiving BMT; this was 20% at 1 year. These results were in accordance with those found by others in pediatric patients undergoing PBPCT for malignant and non-malignant diseases. 15, 34, 35 The probability of cGVHD in this study was higher in the PBPCT group compared to the BMT group although the difference was not statistically significant. This difference is particularly evident after the first year from transplantation. Because of this, longer follow-up is necessary to address this controversial issue. However, despite differences in cGVHD incidences there is no reported negative influence on event-free survival in pediatric series, 15, 34, 35, 37 which implies a similar TRM and a similar relapse incidence. One could expect a lower probability of leukemia relapse in PBPCT patients because of a cGVHD-related graft-versus-leukemia effect. This effect is very clear in chronic myeloid leukemia and less evident in acute lymphoblastic leukemia.
In conclusion, PBPCT in pediatric patients results in faster hematopoietic recovery compared to BMT, with a similar incidence of aGVHD. However, whether allogeneic PBPCT gives a higher incidence of cGVHD, decreases leukemia relapse or provides any long-term survival benefit over BMT needs to be addressed in the setting of appropiated studies which should include a clinical risk/benefit evaluation for pediatric donors.
